About GlycosBio
GlycosBio is a company based in Houston (United States) founded in 2007 by Richard Cilento. GlycosBio has raised $16.78 million across 8 funding rounds from investors including DFJ, EIV Capital and Mercury Fund. The company has 7 employees as of December 31, 2022. GlycosBio offers products and services including Activated Oil Systems and Bioavailability Research. GlycosBio operates in a competitive market with competitors including Kapiva, ChromaDex, Labomar, Setu and BBetter, among others.
- Headquarter Houston, United States
- Employees 7 as on 31 Dec, 2022
- Founders Richard Cilento
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Glycos Biotechnologies Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.78 M (USD)
in 8 rounds
-
Latest Funding Round
$1.13 M (USD), Series C
Mar 06, 2024
-
Investors
DFJ
& 2 more
-
Employee Count
7
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GlycosBio
GlycosBio offers a comprehensive portfolio of products and services, including Activated Oil Systems and Bioavailability Research.
Enhances therapeutic benefits of natural materials via lipid engineering.
Improves nutrient absorption for patients with gastrointestinal issues.
People of GlycosBio
Unlock access to complete
Unlock access to complete
Funding Insights of GlycosBio
GlycosBio has successfully raised a total of $16.78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $1.13 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series C — $1.1M
-
First Round
First Round
(22 Feb 2008)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series C - GlycosBio | Valuation |
investors |
|
| Apr, 2023 | Amount | Series B - GlycosBio | Valuation |
investors |
|
| Dec, 2016 | Amount | Series B - GlycosBio | Valuation |
investors |
|
Investors in GlycosBio
GlycosBio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include DFJ, EIV Capital and Mercury Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused VC firm
|
Founded Year | Domain | Location | |
|
Growth equity is invested in sustainable energy businesses by EIV Capital.
|
Founded Year | Domain | Location | |
|
Early-stage investments are directed toward US, India, and Canada firms.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GlycosBio
Financial Statements - GlycosBio
Glycosbio Comparisons
Competitors of GlycosBio
GlycosBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kapiva, ChromaDex, Labomar, Setu and BBetter, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Ayurvedic healthcare and nutritional products are provided by Kapiva.
|
|
| domain | founded_year | HQ Location |
Nutritional ingredients for health and wellness are developed.
|
|
| domain | founded_year | HQ Location |
Dietary supplements, diet foods, health products, and medical devices
|
|
| domain | founded_year | HQ Location |
Dietary supplements with herbal extracts and vitamins are provided.
|
|
| domain | founded_year | HQ Location |
Nutritional supplements are provided to enhance health and wellness.
|
|
| domain | founded_year | HQ Location |
Nutritional products for various health ailments are provided.
|
Frequently Asked Questions about GlycosBio
GlycosBio was founded in 2007 and raised its 1st funding round 1 year after it was founded.
GlycosBio is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
GlycosBio is a funded company, having raised a total of $16.78M across 8 funding rounds to date. The company's 1st funding round was a Series B of $829.85K, raised on Feb 22, 2008.
As of Dec 31, 2022, the latest employee count at GlycosBio is 7.
GlycosBio is a scientifically focused biotechnology company with expertise in molecular biology as well as metabolic engineering. The company leverages metabolic engineering and associated process development for the production of specialty chemicals like Lactic Acid and Isoprene from crude glycerol, palm fatty acid distillates, and glucose for the preparation of food additives, biodegradable plastics, etc. GlycosBios nutraceuticals platform also supports the production of food ingredients like Non-GMO enriched proteins, dietary fiber, concentrated omega-3 fatty acids and probiotics from rice bran, fish and algal oil, and palm kernel cake.
GlycosBio offers Activated Oil Systems and Bioavailability Research.
GlycosBio has 3 investors. Key investors include DFJ, EIV Capital, and Mercury Fund.